RxDoctor Payments Data

Lora Martin

Family · Little River, SCNPI 1598451536

Payments from drug & device makers

$2,761in general payments, 2019–2025

Across 59 payments — averaging $46.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1K
  • Biotronik Inc.$316
  • Medtronic$264
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$264
  • Edwards Lifesciences$175
  • Biosense Webster, Inc.$127
  • plus $293 from 12 others

What the payments were for

  • Travel & lodging$58821%
  • Food & beverage$2,17379%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,761 in reported general payments places this provider in the 80th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$71,817
Medicare patients
289
Services billed
1,083

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban156$180,193
XareltoRivaroxaban45$42,248
MultaqDronedarone Hcl12$22,242
Dofetilide91$18,749
FarxigaDapagliflozin Propanediol16$12,878
Metoprolol Succinate138$2,873
Sucralfate114$2,655
Flecainide Acetate43$1,176
Diltiazem 24hr Er (Cd)Diltiazem Hcl39$1,021
Metoprolol Tartrate78$848
Diltiazem Hcl36$681
Amiodarone Hcl49$664
Cephalexin152$548
Pantoprazole Sodium91$433
Carvedilol29$324

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$16$180,193156 claims
Johnson & JohnsonXarelto$27$42,24845 claims
AstraZenecaFarxiga$17$12,87816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,248 family providers in South Carolina.

Other family in Little River

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →